Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 13/20 | 0.70 |
| ▸ | BRAF | P15056 | 1/20 | 0.58 |
| ▸ | BCR | P11274 | 7/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13621817 | 0.88 | ABL1 (0.55) | ABL1BRAFBCRKDM4EMAPT | |
| SCHEMBL4358482 | 0.87 | ABL1 (0.58) | ABL1BRAFBCRKDM4EMAPT | |
| SCHEMBL4358479 | 0.85 | ABL1 (0.55) | ABL1BRAFBCRKDM4EMAPT | |
| SCHEMBL10013582 | 0.82 | ABL1 (1.00) | ABL1BRAFBCRKDM4EMAPT | |
| SCHEMBL4005052 | 0.82 | ABL1 (0.50) | ABL1BRAFBCRKDM4EMAPT | |
| SCHEMBL13632490 | 0.81 | PLK1 (0.52) | ABL1MAPT | |
| SCHEMBL3996627 | 0.81 | ABL1 (0.49) | ABL1BRAFBCRKDM4EMAPT | |
| SCHEMBL3452445 | 0.81 | ABL1 (0.66) | ABL1BRAFBCRKDM4EMAPT | |
| SCHEMBL3996127 | 0.81 | ABL1 (0.70) | ABL1BRAFBCRKDM4EMAPT | |
| SCHEMBL25602455 | 0.80 | ABL1 (0.60) | ABL1BCRMAPTTP53ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084644-A1 | Novel pyridine compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-04-20 | — | — | US | claimed |
| US-7622486-B2 | Pyridine compounds, process for their preparation and compositions containing them | REDDY US THERAPEUTICS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622486-B2 | Pyridine compounds, process for their preparation and compositions containing them | REDDY US THERAPEUTICS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622486-B2 | Pyridine compounds, process for their preparation and compositions containing them | REDDY US THERAPEUTICS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20060084644-A1 | Novel pyridine compounds, process for their preparation and compositions containing them | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084644-A1 | Novel pyridine compounds, process for their preparation and compositions containing them | LDLR, LRP6, PLPBP | ABL1 3158/4885BRAF 1104/4885BCR 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.